Literature DB >> 7743477

Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas.

T Nitta1, K Sato.   

Abstract

BACKGROUND: The goal of treating patients with malignant gliomas by intracranial surgery has been to remove as much tumor as possible without causing new neurologic deficits. However, it is still debatable whether the degree of surgical resection correlates with survival times of patients with supratentorial gliomas.
METHODS: One hundred and one patients with supratentorial malignant gliomas who underwent either a gross total resection, a subtotal resection, and/or a partial resection were examined. A correlation between their length of survival and the degree of surgical resection was determined.
RESULTS: The survival rates of patients who underwent total resections were significantly higher than those of patients who underwent subtotal or partial resections (P < 0.01). However, there was no significant difference in the survival rates between the subtotal and partial resection groups. These results also were confirmed by independent variables, such as age, location of the tumors, and histologic subtypes, with the exceptions of temporal gliomas and those younger than 60 years.
CONCLUSIONS: The favorable prognosis of patients with malignant gliomas depends upon the total resection of these tumors. These findings should be of help in designing preoperative surgical intervention strategies.

Entities:  

Mesh:

Year:  1995        PMID: 7743477     DOI: 10.1002/1097-0142(19950601)75:11<2727::aid-cncr2820751115>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  38 in total

Review 1.  Extent of resection as a prognostic variable in the treatment of gliomas.

Authors:  K R Hess
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

2.  The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.

Authors:  Meral Y Sayin; Bektas Kaya; Bekir H Bakkal; Kadri Altundag; Muzaffer B Altundag
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

3.  Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery.

Authors:  Timothy C Ryken; Bruce Frankel; Terrance Julien; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

Review 4.  Operative techniques for gliomas and the value of extent of resection.

Authors:  Nader Sanai; Mitchel S Berger
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

5.  Novel Surgical Approaches to High-Grade Gliomas.

Authors:  Fahid Tariq Rasul; Colin Watts
Journal:  Curr Treat Options Neurol       Date:  2015-09       Impact factor: 3.598

6.  A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.

Authors:  J M Sepúlveda; C Belda-Iniesta; M Gil-Gil; P Pérez-Segura; A Berrocal; G Reynés; O Gallego; J Capellades; J M Ordoñez; B La Orden; C Balañá
Journal:  Clin Transl Oncol       Date:  2015-06-02       Impact factor: 3.405

7.  Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study.

Authors:  G Fountzilas; A Karavelis; A Capizzello; A Kalogera-Fountzila; G Karkavelas; N Zamboglou; P Selviaridis; G Foroglou; A Tourkantonis
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

Review 8.  Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme.

Authors:  Joseph A Hanson; Frank P K Hsu; Arun T Jacob; Daniela A Bota; Daniela Alexandru
Journal:  Perm J       Date:  2013

Review 9.  Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?

Authors:  Romain Mathieu; Stephan M Korn; Karim Bensalah; Gero Kramer; Shahrokh F Shariat
Journal:  World J Urol       Date:  2016-08-08       Impact factor: 4.226

10.  In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes.

Authors:  Conroy Sun; Omid Veiseh; Jonathan Gunn; Chen Fang; Stacey Hansen; Donghoon Lee; Raymond Sze; Richard G Ellenbogen; Jim Olson; Miqin Zhang
Journal:  Small       Date:  2008-03       Impact factor: 13.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.